Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 6;81(4):e128-e131.
doi: 10.1093/cid/ciaf204.

Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study

Tom Loosli  1   2 , Carolyn Bolton Moore  3   4 , Lydia Buzaalirwa  5 , Helen Byakwaga  6 , İpek Çelikağ  7 , Cleophas Chimbetete  8 , Peter Vanes Ebasone  9 , Jennifer Giandhari  10 , Nuri Han  1   2 , Jacqueline Huwa  11 , Charles Kasozi  12 , Adolphe Mafoua  13 , Eugène Messou  14 , Albert Minga  15 , Guy Muula  3 , Winnie Muyindike  6 , Arcel Christ Massamba Ndala  16 , Mamatha Sauermann  7 , Aggrey Semeere  17 , Lavanya Singh  10 , Roger D Kouyos  1   2 , Richard Lessells  10   18 , Matthias Egger  7   19   20
Affiliations

Drug Resistance in People With Viremia on Dolutegravir-based Antiretroviral Therapy in Sub-Saharan Africa: The DTG RESIST Study

Tom Loosli et al. Clin Infect Dis. .

Abstract

Dolutegravir resistance is an increasing concern. An analysis of the DTG RESIST study found that among 227 integrase sequences from 7 African countries (all non-B subtypes), 59 (26.0%) had at least 1 major drug resistance mutation (primarily G118R and E138A/K/T), with 49 (21.6%) predicted to have high-level resistance to dolutegravir.

Keywords: HIV; dolutegravir; drug resistance; sub-Saharan Africa; viremia.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest . R. D. K. has received financial support (payment to the institution) for the present work from the NIH NIAID and has received grants from Gilead Sciences. R. L. has received financial support (payment to the institution) for the present work from the NIH NIAID and has received grants (payment to institution) from the NIH NIAID for an unrelated project. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
INSTI DRMs in people with non-B HIV-1 experiencing virological failure on DTG-based ART in 7 African countries. A, INSTI DRMs among individuals with 1 or more major INSTI DRMs and, among the latter, the most frequent combinations of INSTI DRMs. B, Number of major INSTI DRMs. (C) HIV subtypes in those with integrase sequences and proportion with 1 or more major INSTI DRMs. Subtypes labeled as other include H (N = 3), unknown (N = 3), J (N = 1), and F (05_DF) (N = 1). Abbreviations: ART, antiretroviral therapy; DRM, drug resistance mutation; DTG, dolutegravir; HIV, human immunodeficiency virus; INSTI, integrase strand transfer inhibitor; PWH, people with human immunodeficiency virus.
See this image and copyright information in PMC

References

    1. World Health Organization. Update of recommendations on first- and second-line antiretroviral regimens. Available at: https://www.who.int/publications/i/item/WHO-CDS-HIV-19.15. Accessed 23 December 2024.
    1. Chu C, Tao K, Kouamou V, et al. Prevalence of emergent dolutegravir resistance mutations in people living with HIV: a rapid scoping review. Viruses 2024; 16:399. - PMC - PubMed
    1. Loosli T, Hossmann S, Ingle SM, et al. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis. Lancet HIV 2023; 10:e733–41. - PMC - PubMed
    1. da Silva J, Pals S, Chang J, Hackett S, Godfrey C, Raizes E. Monitoring emerging human immunodeficiency virus drug resistance in sub-Saharan Africa in the era of dolutegravir. J Infect Dis 2022; 225:364–6. - PubMed
    1. Bernabé KJ, Siedner M, Tsai AC, Marconi VC, Murphy RA. Detection of HIV virologic failure and switch to second-line therapy: a systematic review and meta-analysis of data from sub-Saharan Africa. Open Forum Infect Dis 2022; 9:ofac121. - PMC - PubMed

MeSH terms